Diabetes Is Associated with Clinical Decompensation Events in Patients with Cirrhosis
- 565 Downloads
Liver cirrhosis is a leading cause of morbidity and mortality in the USA. Diabetes is common and increasing in incidence. Patients with compensated cirrhosis and diabetes may be at greater risk of clinical decompensation. We examined the risk of decompensation among a large sample of working-aged insured patients dually diagnosed with compensated cirrhosis and diabetes.
This retrospective study used MarketScan® Commercial Claims and Encounters and Medicare Supplemental Databases (2000–2013). Decompensation events included incident ascites, spontaneous bacterial peritonitis, variceal bleeding, hepatic encephalopathy, acute renal failure, and hepatocellular carcinoma. Dually diagnosed patients were defined as patients with cirrhosis and diabetes using previously published ICD-9 coding strategies. Adjusted odds ratios (ORs), hazard ratios (HRs), and confidence intervals (CI) were estimated using logistic regression and Cox proportional hazard models.
Of 72,731 patients with compensated cirrhosis, 20,477 patients (28.15 %) were diagnosed with diabetes. After controlling for patient characteristics and medication usage, the odds of developing any decompensation event were 1.14 times higher for patients with cirrhosis and diabetes than for patients with cirrhosis only (95 % CI 1.08–1.21, P value <0.01). In the Cox proportional hazard model, patients who were dually diagnosed with diabetes had a 1.32 times higher HR (95 % CI 1.26–1.39, P value <0.01) after controlling for time-to-event.
Patients dually diagnosed with compensated cirrhosis and diabetes had a higher risk of having decompensation events. Careful management of diabetes in patients with liver disease may reduce the risk of clinical decompensation in this population.
KeywordsLiver diseases Multiple chronic conditions Secondary data
The database infrastructure used for this project was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health; the Cecil G. Sheps Center for Health Services Research, UNC; the CER Strategic Initiative of UNC’s Clinical Translational Science Award (1 ULI RR025747); and the UNC School of Medicine. Tsai-Ling Liu was supported by a predoctoral Fellowship from Worldwide Health Economics and Outcomes Research at Bristol-Myers Squibb (BMS). BMS had no role in the study design, analysis, interpretation; preparation, review, approval, or decision to submit the manuscript for publication. Morris Weinberger was supported by a VA Health Services Research Senior Career Scientist Award (RCS 91-408).
This study was sponsored by a predoctoral Fellowship from Worldwide Health Economics and Outcomes Research at Bristol-Myers Squibb when the research was conducted. The funding and supporting organization had no role in the study design, analysis, interpretation of the data, preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Neff GW, Duncan CW, Schiff ER. The current economic burden of cirrhosis. Gastroenterol Hepatol (NY). 2011;7:661–671.Google Scholar
- 19.CDC. Long-term Trends in Diabetes. CDC's Division of Diabetes Translation; 2014:1–6.Google Scholar
- 20.CDC. Deaths: final data for 2012. Natl Vital Stat Rep. 2012;63:1–85.Google Scholar
- 21.Hansen LG, Chang S. Health Research Data for the Real World: The MarketScan ® Databases; 2013:1–48.Google Scholar
- 30.CMS. Quality Rating System—Measure Technical Specifications; 2014:1–175.Google Scholar
- 40.Skyler JS, Bergenstal R, Bonow RO, et al. Intensive Glycemic Control and the Prevention of Cardiovascular Events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials. A position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology. J Am Coll Cardiol. 2009;53:298–304.CrossRefPubMedGoogle Scholar